Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death. By Gina Kolata A ...
Clinical Trials Arena on MSN
BMS to speak with regulators on mid-stage multiple myeloma success
An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback